SCG
NKTR icon

Strategic Capital Group’s Nektar Therapeutics NKTR Stock Holding History

Strategic Capital Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$23K Hold
120
– – 0.01% 237
2014
Q1 		$22K Sell
120
-17
-12% -$3.36K 0.01% 272
2013
Q4 		$23K Buy
137
+34
+33% +$5.48K 0.02% 206
2013
Q3 		$16K Sell
103
-17
-14% -$3.14K 0.01% 242
2013
Q2 		$21K Buy
+120
New +$18.4K 0.01% 218

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Strategic Capital Group's NKTR Position: Q2 2014 in Review

Strategic Capital Group held its Nektar Therapeutics (NKTR) position steady in Q2 2014 at 120 shares worth $23K. The position accounts for 0.01% of the portfolio, ranked #237.

Strategic Capital Group first reported a position in NKTR in Q2 2013 and has held it in 5 quarters since. 144 funds tracked by Wall St. Rank hold NKTR as of Q2 2014.

  • Strategic Capital Group held 120 shares of Nektar Therapeutics worth $23K as of Q2 2014.
  • Strategic Capital Group left its Nektar Therapeutics share count unchanged in Q2 2014.
  • Nektar Therapeutics made up 0.01% of Strategic Capital Group's portfolio in Q2 2014, its #237 holding.
  • Strategic Capital Group first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 5 quarters since.
  • 144 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2014.

Based on Strategic Capital Group's 13F filing for Q2 2014, filed 14 Jul 2014.